Old Mission Capital
ESPR icon

Old Mission Capital’s Esperion Therapeutics ESPR Stock Holding History

Old Mission Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-52,029
Closed -$72.3K – 1361
2023
Q2 		$72.3K Buy
+52,029
New +$72.6K ﹤0.01% 1117

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Old Mission Capital's ESPR Position: Q3 2023 in Review

Old Mission Capital sold out of Esperion Therapeutics (ESPR) in Q3 2023, closing a stake of 52,029 shares — an estimated $72.3K sold.

Old Mission Capital first reported a position in ESPR in Q2 2023 and held it in 1 quarter. The position peaked at $72.3K in Q2 2023. 122 funds tracked by Wall St. Rank hold ESPR as of Q3 2023.

  • Old Mission Capital reported no remaining Esperion Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Old Mission Capital sold 52,029 Esperion Therapeutics shares in Q3 2023, an estimated $72.3K.
  • Old Mission Capital first reported a position in Esperion Therapeutics in Q2 2023 and held it in 1 quarter.
  • Old Mission Capital's Esperion Therapeutics position peaked at $72.3K in Q2 2023.
  • 122 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2023.

Based on Old Mission Capital's 13F filing for Q3 2023, filed 15 Nov 2023.